{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:07:27Z","timestamp":1790698047594,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Introduction<\/jats:title>\n          <jats:p>Dose response of 22 patients experiencing mCRPC (metastatic castration-resistant prostate cancer) to <jats:sup>177<\/jats:sup>Lu-PSMA I&amp;T radionuclide therapy was investigated. Dosimetry calculations are used to assess correlations between dosimetric quantities and biomarker values.<\/jats:p>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The patients\u2019 age range was 74 \u00b1 7 years at the time of the investigated treatment cycle, and the mean injected activity was 7416 \u00b1 218 MBq. Planar images at several time points postinjection were used for evaluation of absorbed doses to organs and lesion. <jats:sup>68<\/jats:sup>Ga-PSMA PET\/CT follow-up imaging enabled the determination of individual tumor molecular volume (TMV) shrinkage. Changes in 7 different biomarkers after the first treatment cycle were correlated with the calculated absorbed organ and TMV doses, resulting in a total number of 259 investigated correlations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixty-three TMVs were identified in the bone, lymph node, and liver tissue with an average reduction of 32.3%, 84.7%, and 72.9%, respectively. Absorbed doses per unit of administered activity for organs and lesions show good agreement with previous works (0.77, 0.71, and 0.27 mGy\/MBq for parotid gland, kidneys, and liver as well as 4.38, 5.47, and 4.95 mGy\/MBq for bone, lymph node, and liver malignancies, respectively). Only 37 of 259 possible correlations turned out to be statistically significant, 26 of which are associated with the absorbed dose of an organ and the decrease of alkaline phosphatases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Although treatment with <jats:sup>177<\/jats:sup>Lu-PSMA I&amp;T leads to a big reduction of TMV in patients with mCRPC, the lack of correlations calls for studies using voxel-wise dosimetry based on SPECT\/CTs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003157","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:21:22Z","timestamp":1601500882000},"page":"661-667","source":"Crossref","is-referenced-by-count":25,"title":["Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&amp;T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Sandra","family":"Barna","sequence":"first","affiliation":[{"name":"Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hartenbach","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Grubm\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Vienna, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Blaickner","sequence":"additional","affiliation":[{"name":"Preclinical Molecular Imaging, AIT Austrian Institute of Technology GmbH, Seibersdorf"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"bib1-20230925","first-page":"145","article-title":"Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET\/CT: preliminary report of in six patients","volume":"3","year":"2015","journal-title":"Ann Transl Med"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000277","article-title":"Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine","volume":"28","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.116.186841","article-title":"Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive?","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cpet.2013.08.014","article-title":"Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy","volume":"9","year":"2014","journal-title":"PET Clin"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2011.06.1957","article-title":"Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007","volume":"83","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2005.09.003","article-title":"Dose-response in stereotactic irradiation of lung tumors","volume":"77","year":"2005","journal-title":"Radiother Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ijrobp.2010.12.029","article-title":"Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy","volume":"82","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumor response to 90 Y- and 177 Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka Experience Since 2013","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177 Lu-PSMA I&T in metastatic castration-resistant prostate cancer: absorbed dose in normal organs and tumor lesions","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/RLU.0000000000002210","article-title":"Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib19-20230925","first-page":"37S","article-title":"MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","year":"1999","journal-title":"J Nucl Med"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1118\/1.597057","article-title":"A preliminary phantom study on a proposed model for quantification of renal planar scintigraphy","volume":"20","year":"1993","journal-title":"Med Phys"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","year":"2017","journal-title":"EJNMMI Res"},{"key":"bib22-20230925","first-page":"288","article-title":"Volume measurements of human parotid and submandibular glands","volume":"46","year":"2014","journal-title":"Beijing Da Xue Xue Bao"},{"key":"bib24-20230925","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","year":"2005","journal-title":"J Nucl Med"},{"key":"bib25-20230925","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD Pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD Pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response\u2013implications for radionuclide therapy","volume":"49","year":"2008","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:08:24Z","timestamp":1695622104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003157","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}